Compare PEPG & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEPG | RMNI |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.6M | 351.4M |
| IPO Year | 2022 | N/A |
| Metric | PEPG | RMNI |
|---|---|---|
| Price | $5.23 | $3.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $9.50 | $5.67 |
| AVG Volume (30 Days) | ★ 806.6K | 306.8K |
| Earning Date | 11-12-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $425,959,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.12 |
| P/E Ratio | ★ N/A | $8.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $1.95 |
| 52 Week High | $6.85 | $5.38 |
| Indicator | PEPG | RMNI |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 47.43 |
| Support Level | $5.04 | $3.74 |
| Resistance Level | $6.72 | $3.89 |
| Average True Range (ATR) | 0.58 | 0.16 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 25.56 | 61.42 |
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.